Compare SAP SE (SAP) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SAP SE vs Vertex Pharmaceuticals Incorporated — how do they compare? SAP SE trades at $206.54 (market cap $240.81B), while Vertex Pharmaceuticals Incorporated trades at $529.62 (market cap $134.25B). The key difference: SAP SE is the larger of the two by market cap, and SAP SE pays a 1.4% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| SAP | VRTX | |
|---|---|---|
Market Cap | $240.81B | $134.25B |
Sector | Technology | Health |
52-Week High | $280.46 | $529.65 |
52-Week Low | $146.38 | $376.62 |
Enterprise Value | $239.52B | $128.37B |
Dividend Yield | 1.4% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
